CLINICAL_TRIALS
trial_result
· 2013-06-19
Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma [Phase 2]
Summary
Phase 2 trial of arsenic trioxide in relapsed or refractory non-Hodgkin lymphoma has completed, with study results reported.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED